ストックスクリーナーアプリを入手
2.61
6.10%
0.15
アフターアワーズ：
2.54
-0.07
-2.68%
前日終値:
$2.46
開ける：
$2.45
24時間の取引高:
1.60M
Relative Volume:
0.80
時価総額：
$185.76M
収益：
$20.76M
当期純損益:
$-132.49M
株価収益率:
-0.9775
EPS:
-2.67
ネットキャッシュフロー:
$-108.55M
1週間 パフォーマンス:
+6.53%
1か月 パフォーマンス:
+17.57%
6か月 パフォーマンス:
+59.15%
1年 パフォーマンス:
-51.03%
1日の値動き範囲:
$2.38
$2.62
1週間の範囲:
$2.38
$2.7899
52週間の値動き範囲:
$1.085
$6.52
C 4 Therapeutics Inc Stock (CCCC) Company Profile
CCCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.61 | 228.94M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-15 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
C4 Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in C4 The - GuruFocus
C4 Therapeutics Inc. stock trend forecastTrade Risk Report & Community Consensus Stock Picks - newser.com
How strong is C4 Therapeutics Inc. stock balance sheet2025 Buyback Activity & Technical Pattern Based Buy Signals - Fundação Cultural do Pará
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What hedge fund activity signals for C4 Therapeutics Inc. stockMarket Movers & Low Drawdown Investment Ideas - Fundação Cultural do Pará
Ptc therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics Inc. stock retracement – recovery analysisMarket Performance Summary & Proven Capital Preservation Tips - newser.com
How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Full technical analysis of C4 Therapeutics Inc. stockQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
Volatility clustering patterns for C4 Therapeutics Inc.July 2025 Closing Moves & Consistent Income Trade Ideas - newser.com
C4 Therapeutics (NASDAQ:CCCC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
How C4 Therapeutics Inc. stock reacts to oil pricesEarnings Overview Summary & Community Consensus Picks - newser.com
C4 Therapeutics (CCCC) Expected to Announce Earnings on Thursday - MarketBeat
Applying chart zones and confluence areas to C4 Therapeutics Inc.2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Live market analysis of C4 Therapeutics Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Candlestick signals on C4 Therapeutics Inc. stock todayJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Will C4 Therapeutics Inc. stock benefit from commodity pricesEarnings Risk Report & Low Risk High Win Rate Stock Picks - Trung tâm Dự báo KTTV quốc gia
Will C4 Therapeutics Inc. stock maintain momentum in 20252025 Price Targets & Community Consensus Trade Alerts - Trung tâm Dự báo KTTV quốc gia
CEO Moves: Will C4 Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Analysis & Weekly Consistent Profit Watchlists - Trung tâm Dự báo KTTV quốc gia
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
C4 Therapeutics Announces Stock and Warrants Offering - TipRanks
Revenues Working Against C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Share Price Following 38% Dive - 富途牛牛
C4 Therapeutics Lines Up $125 Million To Fund Cancer Trials - Finimize
C4 Therapeutics (CCCC) to Raise $125M Through Stock and Warrant Offering - GuruFocus
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - Investing News Network
C4 Therapeutics, Inc. Announces $125 Million Underwritten Offering to Advance Cemsidomide Multiple Myeloma Development - Quiver Quantitative
$125M Upfront — C4 Therapeutics Prices Offering to Fund Cemsidomide Trials; May Reach $349.7M - Stock Titan
C4 Therapeutics Presents Phase 1 Trial Data - TipRanks
C4 Therapeutics, Inc. Presents Phase 1 Trial Data for Cemsidomide - TradingView
C4 Therapeutics prices equity deal; warrants could lift net to $341.7M - Stock Titan
Is C4 Therapeutics Inc. still worth holding after the dipStop Loss & Weekly High Return Opportunities - newser.com
When is the best time to exit C4 Therapeutics Inc.Recession Risk & AI Based Buy and Sell Signals - newser.com
Real time social sentiment graph for C4 Therapeutics Inc.2025 Valuation Update & Precise Buy Zone Tips - newser.com
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):